Drug Trial Radar · NCT01968109
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,482
Actual
Start
Nov 5, 2013
Primary completion
May 22, 2024
Study completion Feb 3, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.
Conditions
- Neoplasms by Site
Interventions
RelatlimabBiological
NivolumabBiological
BMS-986213Biological
Relatlimab + Nivolumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory AbnormalitiesTime frame: From first dose and within 135 days after last dose of study therapy (Up to approximately 82 months)
- Part C, D1, D2, E - Objective Response Rate Per BICRTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
- Part C, D1, D2, E - Disease Control Rate (DCR) Per BICRTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
- Part C, D1, D2, E - Duration of Response (DOR) Per BICRTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 127 months)
- Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study TherapyTime frame: From first dose and within 2 days of first dose of study therapy
- Part C, D1, D2, E - Objective Response Rate Per BICRTime frame: From first dose (Day 1) and up to 97 months
Locations
54 sites in 15 countries. Site status is shown where the registry gives one.
Local Institution - 0043
La Jolla, California
Local Institution - 0053
Aurora, Colorado
Local Institution - 0058
Tampa, Florida
Local Institution - 0003
Chicago, Illinois
Local Institution - 0048
Niles, Illinois
Local Institution - 0004
Baltimore, Maryland
Local Institution - 0001
Boston, Massachusetts
Local Institution - 0011
Detroit, Michigan
Local Institution - 0051
Rochester, Minnesota
Local Institution - 0044
St Louis, Missouri
Local Institution - 0005
New York, New York
Local Institution - 0002
Portland, Oregon
Local Institution - 0047
Allentown, Pennsylvania
Local Institution - 0010
Pittsburgh, Pennsylvania
Local Institution - 0057
Dallas, Texas
Local Institution - 0045
Houston, Texas
Local Institution - 0008
Seattle, Washington
Local Institution - 0029
North Sydney, New South Wales, Australia
Local Institution - 0031
Brisbane, Queensland, Australia
Local Institution - 0039
Southport, Queensland, Australia
Local Institution - 0033
Melbourne, Victoria, Australia
Local Institution - 0032
Nedlands, Western Australia, Australia
Local Institution - 0023
Vienna, Austria
Local Institution - 0024
Vienna, Austria
Local Institution - 0049
Toronto, Ontario, Canada
Local Institution - 0050
Québec, Quebec, Canada
Local Institution - 0028
Copenhagen, Denmark
Local Institution - 0020
Herlev, Denmark
Local Institution - 0021
Helsinki, Uusimaa, Finland
Local Institution - 0038
Marseille, France
Local Institution - 0037
Nantes, France
Local Institution - 0036
Pierre-Bénite, France
Local Institution - 0026
Toulouse, France
Local Institution - 0018
Villejuif, France
Local Institution - 0007
Essen, Germany
Local Institution - 0040
Heilbronn, Germany
Local Institution - 0041
Würzburg, Germany
Local Institution - 0014
Milan, Italy
Local Institution - 0013
Naples, Italy
Local Institution - 0035
Padova, Italy
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.